{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:14:33Z","timestamp":1788394473708,"version":"build-2803163510"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Seagen, which was acquired by Pfizer in December 2023"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the HER2CLIMB study (NCT02614794), tucatinib in combination with trastuzumab and capecitabine (TTC) significantly improved progression-free survival and overall survival compared with the placebo combination with a manageable safety profile in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). Based on these findings, the TTC regimen was approved by the US Food and Drug Administration in April 2020 for the treatment of patients with HER2+ MBC, including those with brain metastases, after receiving at least 1 prior anti-HER2 therapy in the metastatic setting. Currently, the TTC regimen is the preferred option for third-line treatment in HER2+ MBC and is an option in the second-line setting for patients with brain metastases. As a multidrug regimen, TTC offers enhanced efficacy with dual inhibition of HER2, both extra- and intracellularly, added to the cytotoxic actions of capecitabine. However, some challenges exist with the TTC regimen related to off-target specific drug toxicities and overlapping adverse events (AEs); the most common being diarrhea, liver enzyme elevations, and palmar-plantar erythrodysesthesia. This article aims to describe the clinical presentation of AEs most frequently requiring dose modifications of the TTC regimen and review their clinical management detailed with visual algorithms that incorporate expert medical guidance gained from experience in managing the TTC regimen in routine clinical practice. With the evolving treatment landscape in earlier line settings for HER2+ MBC, patients may now be treated with different first- and second-line therapies from those available when HER2CLIMB was conducted and this may impact its safety profile.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag330","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:43:50Z","timestamp":1787312630000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical management of adverse events in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2068-2593","authenticated-orcid":false,"given":"Alicia F C","family":"Okines","sequence":"first","affiliation":[{"name":"Medical Oncology, The Royal Marsden NHS Foundation Trust , London, SW3 6JJ,","place":["United Kingdom"]},{"name":"Institute of Cancer Research , London, SW7 3RP,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Roesch","sequence":"additional","affiliation":[{"name":"Hematology\/Medical Oncology, Cleveland Clinic , Cleveland, OH 44195,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2211-1040","authenticated-orcid":false,"given":"Karen","family":"Watkins","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, NY 10001,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7423-6072","authenticated-orcid":false,"given":"Mary Kathryn","family":"Pitner","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, NY 10001,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6221-8905","authenticated-orcid":false,"given":"Katie M","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"Pfizer Inc , San Diego, CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Simon","sequence":"additional","affiliation":[{"name":"Pfizer S.L.U. , Madrid 28108,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0234-4937","authenticated-orcid":false,"given":"Fengting","family":"Yan","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center Seattle, WA 98109,","place":["United States"]},{"name":"Division of Hematology & Oncology, University of Washington , Seattle, WA 98109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"2026090219265251100_oyag330-B1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"2026090219265251100_oyag330-B2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","article-title":"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis","volume":"33","author":"Curigliano","year":"2022","journal-title":"Ann Oncol"},{"key":"2026090219265251100_oyag330-B3","author":"US Food and Drug Administration","year":"2025"},{"key":"2026090219265251100_oyag330-B4","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/jco.22.00519","article-title":"Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update","volume":"40","author":"Giordano","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026090219265251100_oyag330-B5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/jco.22.00520","article-title":"Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update","volume":"40","author":"Ramakrishna","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026090219265251100_oyag330-B6","doi-asserted-by":"publisher","first-page":"e2300285","DOI":"10.1200\/go.23.00285","article-title":"Systemic treatment of patients with metastatic breast cancer: ASCO resource-stratified guideline","volume":"10","author":"Al Sukhun","year":"2024","journal-title":"JCO Glob Oncol."},{"key":"2026090219265251100_oyag330-B7","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41571-024-00939-2","article-title":"Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance","volume":"21","author":"Waks","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026090219265251100_oyag330-B8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10549-016-3756-5","article-title":"A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis","volume":"156","author":"Nishijima","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2026090219265251100_oyag330-B9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ejca.2021.05.025","article-title":"Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)","volume":"153","author":"Mueller","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026090219265251100_oyag330-B10","doi-asserted-by":"publisher","first-page":"e2400068","DOI":"10.1200\/oa-24-00068","article-title":"Randomized trial of fixed-dose capecitabine compared with standard-dose capecitabine in metastatic breast cancer: X-7\/7 trial","volume":"2","author":"Khan","year":"2025","journal-title":"JCO Oncol Adv"},{"key":"2026090219265251100_oyag330-B11","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1158\/1078-0432.Ccr-16-1496","article-title":"Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2(+)-advanced solid tumors, with an expansion cohort in HER2(+) metastatic breast cancer (MBC)","volume":"23","author":"Moulder","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026090219265251100_oyag330-B12","author":"National Institute of Diabetes and Digestive and Kidney Diseases","year":"2026"},{"key":"2026090219265251100_oyag330-B13","article-title":"Tucatinib. National Institute of Diabetes and Digestive and Kidney Diseases","author":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2026"},{"key":"2026090219265251100_oyag330-B14","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1200\/JCO.2020.38.15_suppl.104","article-title":"Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)","volume":"38","author":"Okines","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026090219265251100_oyag330-B15","doi-asserted-by":"publisher","first-page":"iv126","DOI":"10.1093\/annonc\/mdy145","article-title":"Diarrhoea in adult cancer patients: ESMO clinical practice guidelines","volume":"29","author":"Bossi","year":"2018","journal-title":"Ann Oncol"},{"key":"2026090219265251100_oyag330-B16","author":"U.S. Department of Health and Human Services NCI","year":"2026"},{"key":"2026090219265251100_oyag330-B17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/bcp.12449","article-title":"Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials","volume":"78","author":"Iacovelli","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2026090219265251100_oyag330-B18","doi-asserted-by":"publisher","first-page":"10732748241278039","DOI":"10.1177\/10732748241278039","article-title":"Management and mechanisms of diarrhea induced by tyrosine kinase inhibitors in human epidermal growth factor receptor-2-positive breast cancer","volume":"31","author":"Sun","year":"2024","journal-title":"Cancer Control"},{"key":"2026090219265251100_oyag330-B19","doi-asserted-by":"publisher","first-page":"e27531","DOI":"10.1016\/j.heliyon.2024.e27531","article-title":"Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"key":"2026090219265251100_oyag330-B20","author":"Genentech Inc","year":"2026"},{"key":"2026090219265251100_oyag330-B21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3389\/fphar.2016.00414","article-title":"Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments","volume":"7","author":"McQuade","year":"2016","journal-title":"Front Pharmacol"},{"key":"2026090219265251100_oyag330-B22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10549-018-05102-x","article-title":"The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea","volume":"175","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2026090219265251100_oyag330-B23","author":"U.S","year":"2026"},{"key":"2026090219265251100_oyag330-B24","author":"Pfizer Inc","year":"2025"},{"key":"2026090219265251100_oyag330-B25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG Clinical Guideline: evaluation of abnormal liver chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2026090219265251100_oyag330-B26","doi-asserted-by":"publisher","first-page":"103583","DOI":"10.1016\/j.breast.2023.103583","article-title":"Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: data from the GIM14\/BIOMETA study","volume":"72","author":"Di Maio","year":"2023","journal-title":"Breast"},{"key":"2026090219265251100_oyag330-B27","doi-asserted-by":"publisher","first-page":"27990","DOI":"10.18632\/oncotarget.15856","article-title":"Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"2026090219265251100_oyag330-B28","doi-asserted-by":"publisher","first-page":"e01067","DOI":"10.1002\/prp2.1067","article-title":"Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency","volume":"11","author":"Maliepaard","year":"2023","journal-title":"Pharmacol Res Perspect"},{"key":"2026090219265251100_oyag330-B29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00280-022-04429-z","article-title":"Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl","volume":"89","author":"Sun","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026090219265251100_oyag330-B30","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s40262-022-01183-6","article-title":"The pharmacokinetics and safety of tucatinib in volunteers with hepatic impairment","volume":"61","author":"Topletz-Erickson","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2026090219265251100_oyag330-B31","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s40262-022-01144-z","article-title":"Evaluation of safety and clinically relevant drug-drug interactions with tucatinib in healthy volunteers","volume":"61","author":"Topletz-Erickson","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2026090219265251100_oyag330-B32","doi-asserted-by":"publisher","first-page":"100061","DOI":"10.1016\/j.dmd.2025.100061","article-title":"Impact of variation in CYP3A and CYP2C8 on tucatinib metabolic clearance in human liver microsomes","volume":"53","author":"Latham","year":"2025","journal-title":"Drug Metab Dispos"},{"key":"2026090219265251100_oyag330-B33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4143\/crt.2017.562","article-title":"Randomized open label phase III trial of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane: PROCEED trial (KCSG BR 11-01)","volume":"51","author":"Park","year":"2019","journal-title":"Cancer Res Treat"},{"key":"2026090219265251100_oyag330-B34","author":"McLellan","year":"2026"},{"key":"2026090219265251100_oyag330-B35","doi-asserted-by":"publisher","first-page":"47002","DOI":"10.1117\/1.Jbo.21.4.047002","article-title":"Detection of capecitabine (Xeloda\u00ae) on the skin surface after oral administration","volume":"21","author":"Huang","year":"2016","journal-title":"J Biomed Opt"},{"key":"2026090219265251100_oyag330-B36","doi-asserted-by":"publisher","first-page":"442","DOI":"10.4081\/oncol.2020.442","article-title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome","volume":"14","author":"Kwakman","year":"2020","journal-title":"Oncol Rev"},{"key":"2026090219265251100_oyag330-B37","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1200\/jco.23.01730","article-title":"Topical diclofenac for prevention of capecitabine-associated hand-foot syndrome: a double-blind randomized controlled trial","volume":"42","author":"Santhosh","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026090219265251100_oyag330-B38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/jcph.1750","article-title":"Tucatinib inhibits renal transporters OCT2 and MATE without impacting renal function in healthy subjects","volume":"61","author":"Topletz-Erickson","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"2026090219265251100_oyag330-B39","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1056\/NEJMoa2511218","article-title":"Palbociclib for first-line hormone receptor-positive, HER2-positive advanced breast cancer","volume":"394","author":"Metzger","year":"2026","journal-title":"N Engl J Med"},{"key":"2026090219265251100_oyag330-B40","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag330\/70757868\/oyag330.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag330\/70757868\/oyag330.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag330\/70757868\/oyag330.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:27:00Z","timestamp":1788391620000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag330\/8767765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag330","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,6]]},"article-number":"oyag330"}}